Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDC-4182 in advanced gastric and gastroesophageal cancer
NCT06921837Phase 2Recruiting
- Sponsor
- Bolt Biotherapeutics
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of BDC-4182 in gastric adenocarcinoma, gastroesophageal adenocarcinoma, sponsored by Bolt Biotherapeutics. Started May 2025; status: recruiting.
02
Drugs
BDC-4182
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on NCT06921837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06921837.